<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699712</url>
  </required_header>
  <id_info>
    <org_study_id>NIL-CDNP-CT003</org_study_id>
    <nct_id>NCT00699712</nct_id>
  </id_info>
  <brief_title>Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF)</brief_title>
  <acronym>PreCONDITION</acronym>
  <official_title>Multi-Center, Open Label, Dose Escalating, Sequential Group Study to Assess the Hemodynamic Effects, Safety and Tolerability of CD-NP in Patients With Stabilized Acute Heart Failure (AHF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nile Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Momentum Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nile Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To access the efficacy of intravenous (IV) administration of CD-NP on changes in cardiac
      output and wedge pressure in patients with stabilized acute heart failure
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in cardiac output and wedge pressure</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in additional hemodynamic measures</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diuresis and natriuresis during and after administration of study drug</measure>
    <time_frame>36 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of CD-NP</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label regimen of doses 1 and 2 of CDNP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label regimen of doses 2 and 3 of CDNP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label regimen of doses 3 and 4 of CDNP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD-NP (Chimeric natriuretic peptide)</intervention_name>
    <description>Infusion of CDNP at two of four doses</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Hospitalization for AHF

          -  In need of hemodynamic monitoring

        Key Exclusion Criteria:

          -  Administration of intravenous radiographic contrast agent within 7 days prior to
             screening or planned IV contrast media administration in the 4 days after screening or
             acute contrast-induced nephropathy at the time of screening

          -  Current or planned treatment with any IV therapies, including diuretics, vasodilators
             (including nesiritide), vasopressin antagonists, positive inotropic agents and
             vasopressors, or mechanical support

          -  Current or planned ultrafiltration, hemofiltration, or dialysis within 7 days of
             screening

          -  Significant pulmonary disease

          -  Known valvular heart disease

          -  Any organ transplant recipient or patient currently listed for transplant or admitted
             for any transplantation.

          -  Major surgery within 30 days of screening

          -  Other major disability or disease with expected survival less than 6 months.

          -  Major neurologic event, including cerebrovascular events, in the 60 days prior to
             screening

          -  Clinical diagnosis of acute coronary syndrome within 45 days of screening

          -  Troponin T â‰¥ 3 times the upper limit of normal at screening

          -  Significant arrhythmias

          -  Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive
             cardiomyopathy

          -  Liver function abnormality

          -  Administration of an investigational drug or implantation of investigational device,
             or participation in another trial, within 30 days prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsiao Lieu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nile Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gad Cotter, MD</last_name>
    <role>Study Director</role>
    <affiliation>Momentum Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Russian Academy of Medical Sciences</name>
      <address>
        <city>Moscow</city>
        <state>Russia</state>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2008</study_first_submitted>
  <study_first_submitted_qc>June 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2008</study_first_posted>
  <last_update_submitted>March 23, 2009</last_update_submitted>
  <last_update_submitted_qc>March 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Hsiao Lieu, MD / Vice President, Clinical Research</name_title>
    <organization>Nile Therapeutics</organization>
  </responsible_party>
  <keyword>ADHF</keyword>
  <keyword>AHF</keyword>
  <keyword>HF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

